Catalyst Pharmaceuticals, Inc. (CPRX) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong revenue and EPS growth with key product expansions, raised guidance, positive analyst sentiment, technical breakout above resistance, and favorable biotech sector tailwinds make it a compelling short-term growth candidate.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High profitability ⢠Very liquid balance ⢠Cash depresses ROIC CERPx exhibits very strong margins and cash generation with negligible leverage and huge cash reserves, but those large cash balances compress ROIC while the stock trades at a moderate premium.
Price Behavior
Key Price Behavior Insights: ⢠Range-bound ⢠Mild upside ⢠Resistance-capped Support Level: $23.00 Resistance Level: $25.00â$25.25 CPRX is range-bound over the last month with modest upside (about $23.91 â $24.24) and stalled under resistance near $25, requiring a clean break above ~$25.25 for bullish confirmation or a drop below ~$23.00 to turn negative.
Sentiment & News
Key News Insights: ⢠Record revenue ⢠Raised guidance ⢠Analyst optimism Catalyst beat Q4/FY25 estimates with record revenue driven by FIRDAPSE and AGAMREE, issued 2026 revenue guidance of $615â$645M (promoted products +20%+), and prompted analyst upgrades and increased investor engagement.
AI Summary
CPRX has shifted into a capitalâefficient, highâmargin rareâdisease commercial growth story where continued execution on patient identification, reimbursement and disciplined deployment of ~ $709M cash (including a $200M buyback) will determine whether forecasted midâteens revenue growth converts into real shareholder value rather than perpetuating low ROIC. Watch two actionable triggers: the Hetero/FYCOMPA patent outcome (binary downside) and management's cadence/pricing of buybacks or targeted inâlicensing/M&A to materially improve ROIC.
Description
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company based in Coral Gables, Florida, that develops and sells therapies for rare neuromuscular and neurological disorders in the United States. Its marketed products include amifampridine formulations for adult and pediatric Lambert-Eaton myasthenic syndrome, and the company is advancing that therapy into additional neuromuscular indications such as certain forms of myasthenia gravis and spinal muscular atrophy. Catalyst also maintains licensing and collaboration arrangements with third parties, including BioMarin and Endo Ventures, and was founded in 2002 (renamed to its current corporate identity in 2015).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | CPRX | Catalyst Pharmaceuticals, Inc. | Strong revenue and EPS growth with key product expansions, raised guidance, positive analyst sentiment, technical breakout above resistance, and favorable biotech sector tailwinds make it a compelling short-term growth candidate. | Closed | +1.9% |